Abstract
Type 2 diabetic mellitus (DM2) is associated with accelerated thrombotic complications and is characterized by high levels of plasminogen activator inhibitor-1 (PAI-1). Recent studies show that human platelets have high levels of miR-30c and synthesize considerable active PAI-1. The underlying mechanism of how PAI-1 expression is upregulated in DM2 is poorly understood. We now report that hyperglycaemia-induced repression of miR-30c increases PAI-1 expression and thrombus formation in DM2. Bioinformatic analysis and identification of miRNA targets were assessed using luciferase assays, quantitative real-time PCR and western blots in vitro and in vivo. The changes in miR-30c and PAI-1 levels were identified in platelets from healthy and diabetic individuals. We found that miR-30c directly targeted the 3′ UTR of PAI-1 and negatively regulated its expression. miR-30c was negatively correlated with glucose and HbA1c levels in DM2. In HFD-fed diabetic mice, increasing miR-30c expression by lenti-miR-30c significantly decreased the PAI-1 expression and prolonged the time to occlusion in an arterial thrombosis model. Platelet depletion/reinfusion experiments generating mice with selective ablation of PAI-1 demonstrate a major contribution by platelet-derived PAI-1 in the treatment of lenti-miR-30c to thrombus formation. These results provide important implications regarding the regulation of fibrinolysis by platelet miRNA under diabetic mellitus.
Highlights
This study, using purified human platelets, we demonstrated the existence of a miR30c-targeted PAI-1 pathway in platelets of the cardiovascular system
We confirmed that miR-30c (MIMAT0000244) and PAI-1 (NM_000602.3) mRNA were found in the small/total RNA libraries of leukocyte-depleted platelets (LDP) by PCR assay from healthy individuals
LDP isolated from healthy individuals and patients with pre-DM, NCDM and DM-CHD were measured as described above (Fig. 1D), indicating the marked and successful depletion of leukocytes from the starting platelet-rich plasma (PRP)
Summary
This study, using purified human platelets, we demonstrated the existence of a miR30c-targeted PAI-1 pathway in platelets of the cardiovascular system. The gene expression levels of miR-30c and PAI-1 in LDPs were measured by qRT-PCR, and the PAI-1 total antigen was determined by ELISA as described above. The PAI-1 mRNA expression levels were up-regulated and significantly greater in the DM-CHD subjects compared with other groups (Fig. 2C,D).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.